Abstract: The present disclosure provides a stapled peptide and use thereof in preparation of a drug for treating pancreatic cancer, belonging to the technical field of biomedicine. The stapled peptide is prepared by using a linear peptide with an amino acid sequence shown in SEQ ID NO: 1 as a peptide chain template, and replacing i-th and (i+7)-th amino acids of the linear peptide with S5 separately and conducting cyclization; alternatively, replacing n-th and (n+4)-th amino acids of the linear peptide with S5 separately and conducting cyclization; where S5 is 2-amino-2-methyl-6-heptenoic acid; i is a positive integer of less than or equal to 7, and n is a positive integer of less than or equal to 10. The stapled peptide treats LINC00261-deficient pancreatic cancer, N1DARP-deficient pancreatic cancer, or gemcitabine-resistant pancreatic cancer by specifically inhibiting a deubiquitination activity of USP10.

Abstract: The present disclosure provides a stapled peptide and use thereof in preparation of a drug for treating pancreatic cancer, belonging to the technical field of biomedicine. The stapled peptide is prepared by using a linear peptide with an amino acid sequence shown in SEQ ID NO: 1 as a peptide chain template, and replacing i-th and (i+7)-th amino acids of the linear peptide with S5 separately and conducting cyclization; alternatively, replacing n-th and (n+4)-th amino acids of the linear peptide with S5 separately and conducting cyclization; where S5 is 2-amino-2-methyl-6-heptenoic acid; i is a positive integer of less than or equal to 7, and n is a positive integer of less than or equal to 10. The stapled peptide treats LINC00261-deficient pancreatic cancer, N1DARP-deficient pancreatic cancer, or gemcitabine-resistant pancreatic cancer by specifically inhibiting a deubiquitination activity of USP10.